Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
received:
21
01
2021
accepted:
21
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
5
11
2021
Statut:
epublish
Résumé
Granulocyte colony-stimulating factor (G-CSF) has raised much interest because of its role in cocaine addiction in preclinical models. We explored the plasma concentrations of G-CSF in patients diagnosed with substance use disorder (SUD) and highly comorbid psychiatric disorders. In particular, we investigated the association between G-CSF concentrations and comorbid major depressive disorder (MDD) in patients with cocaine and alcohol use disorders (CUD and AUD, respectively). Additionally, patients with MDD but not SUD were included in the study. Three hundred and eleven participants were enrolled in this exploratory study: 136 control subjects, 125 patients with SUD (SUD group) from outpatient treatment programs for cocaine (N = 60, cocaine subgroup) and alcohol (N = 65, alcohol subgroup), and 50 patients with MDD but not SUD (MDD group) from primary-care settings. Participants were assessed based on DSM-IV-TR criteria, and a blood sample was collected to examine the plasma concentrations of G-CSF. G-CSF concentrations were negatively correlated with age in the entire sample (r = - 0.233, p < 0.001) but not in the patients with MDD. G-CSF concentrations were lower in patients with SUD than in controls (p < 0.05), specifically in the cocaine subgroup (p < 0.05). Patients with SUD and comorbid MDD had lower G-CSF concentrations than patients with SUD but not comorbid MDD or controls (p < 0.05). In contrast, patients with MDD but not SUD showed no differences compared with their controls. The negative association between G-CSF concentrations and age in the sample was not observed in patients with MDD. G-CSF concentrations were decreased in patients with SUD and comorbid MDD but not in patients with MDD. Therefore, G-CSF may be useful to improve the stratification of patients with dual diagnosis seeking treatment. Further investigation is needed to explore the impact of sex and type of drug on the expression of G-CSF.
Identifiants
pubmed: 34211033
doi: 10.1038/s41598-021-93075-1
pii: 10.1038/s41598-021-93075-1
pmc: PMC8249412
doi:
Substances chimiques
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13629Références
J Neurochem. 2006 May;97(3):675-86
pubmed: 16573658
Addict Biol. 2017 Sep;22(5):1366-1377
pubmed: 27212249
J Clin Invest. 2005 Aug;115(8):2083-98
pubmed: 16007267
J Exp Med. 2007 Jun 11;204(6):1273-80
pubmed: 17517969
J Neurosci. 2016 Jul 27;36(30):7807-16
pubmed: 27466327
Brain Res. 2005 Oct 5;1058(1-2):120-8
pubmed: 16150422
Neuroscience. 1990;39(1):151-70
pubmed: 2089275
PLoS One. 2017 Nov 6;12(11):e0187634
pubmed: 29108028
PLoS One. 2019 Mar 14;14(3):e0213791
pubmed: 30870525
Haematol Blood Transfus. 1985;29:1-521
pubmed: 4029723
Ann Hepatol. 2019 May - Jun;18(3):518-535
pubmed: 31053546
J Neurosci. 2004 Oct 27;24(43):9714-22
pubmed: 15509760
Pharmacol Rep. 2019 Dec;71(6):1299-1307
pubmed: 31706254
Addict Biol. 2015 Jul;20(4):756-72
pubmed: 24854157
Pharmacol Biochem Behav. 2019 Apr;179:34-42
pubmed: 30695700
Nat Med. 2007 Nov;13(11):1359-62
pubmed: 17934472
Nat Rev Neurosci. 2016 Jun;17(6):351-65
pubmed: 27150400
Pharmacol Ther. 2012 May;134(2):219-45
pubmed: 22316499
Nat Commun. 2018 Jan 16;9(1):9
pubmed: 29339724
Neuropsychopharmacology. 2017 Jan;42(1):156-177
pubmed: 27402494
J Alzheimers Dis. 2009;17(1):115-23
pubmed: 19494436
Exp Neurol. 2008 Apr;210(2):349-58
pubmed: 18190912
Adicciones. 2016 Sep 29;29(2):83-96
pubmed: 27749968
J Korean Med Sci. 2009 Oct;24(5):941-4
pubmed: 19794996
Curr Psychiatry Rep. 2015 Nov;17(11):90
pubmed: 26384339
Behav Brain Res. 2005 Nov 30;165(1):110-25
pubmed: 16105698
Adicciones. 2017 Jan 01;29(1):3-5
pubmed: 28170050
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):201-17
pubmed: 15694227
Pharmacol Rep. 2021 Apr;73(2):346-356
pubmed: 33385173
Child Adolesc Psychiatr Clin N Am. 2016 Apr;25(2):297-305
pubmed: 26980131
PLoS One. 2009;4(4):e5303
pubmed: 19390691
Cytokine. 2000 Sep;12(9):1437-40
pubmed: 10976010
J Psychopharmacol. 2020 Nov;34(11):1250-1260
pubmed: 32536325
Neuropharmacology. 2019 May 1;149:212-220
pubmed: 30822499
Addict Biol. 2019 Sep;24(5):1019-1033
pubmed: 30277635
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):1060-4
pubmed: 20553781
Blood. 1986 Jan;67(1):37-45
pubmed: 3484428
J Psychoactive Drugs. 2017 Sep-Oct;49(4):306-315
pubmed: 28682218
Arch Gen Psychiatry. 1988 Dec;45(12):1069-77
pubmed: 2848472
Addiction. 2014 Aug;109(8):1320-33
pubmed: 24661272
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Aug 16;34(6):846-51
pubmed: 20382196
Hum Psychopharmacol. 2012 Mar;27(2):156-66
pubmed: 22389080
JAMA Psychiatry. 2015 Mar;72(3):268-75
pubmed: 25629589
Am J Psychiatry. 2006 Apr;163(4):689-96
pubmed: 16585445
Front Psychiatry. 2017 Jan 18;7:214
pubmed: 28149283
Science. 1997 Oct 3;278(5335):52-8
pubmed: 9311926
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1417-22
pubmed: 26787898
Biol Psychiatry. 2004 Nov 15;56(10):730-7
pubmed: 15556117
Arch Gen Psychiatry. 2007 Jul;64(7):830-42
pubmed: 17606817
Psychopharmacology (Berl). 2016 May;233(9):1623-36
pubmed: 26803500
J Neurosci. 2002 May 1;22(9):3332-7
pubmed: 11978808
Am J Psychiatry. 2004 Jul;161(7):1231-7
pubmed: 15229056
J Pers Med. 2021 Jan 23;11(2):
pubmed: 33498653
Am J Psychiatry. 2013 Jan;170(1):23-30
pubmed: 23223834
Addiction. 2020 Dec;115(12):2257-2267
pubmed: 32533781